Cellphire, Inc.   Report issue

For profit Phase 3
Founded: Rockville MD United States (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2014
NCT02223117
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cellphire, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

platelets (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Aplastic (Phase 2)

Hematologic Diseases (Phase 1)

Hematologic Neoplasms (Phase 2)

Hemorrhage (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Thrombocytopenia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1